These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 27114600)

  • 1. The First Step to Integrating Adapted Common Terminology Criteria for Adverse Events for Children.
    de Rojas T; Bautista FJ; Madero L; Moreno L
    J Clin Oncol; 2016 Jun; 34(18):2196-7. PubMed ID: 27114600
    [No Abstract]   [Full Text] [Related]  

  • 2. PROceeding With the Patient-Reported Outcomes (PROs) Version of the Common Terminology Criteria for Adverse Events.
    Movsas B
    JAMA Oncol; 2015 Nov; 1(8):1059-60. PubMed ID: 26270250
    [No Abstract]   [Full Text] [Related]  

  • 3. Validity and Reliability of the US National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Dueck AC; Mendoza TR; Mitchell SA; Reeve BB; Castro KM; Rogak LJ; Atkinson TM; Bennett AV; Denicoff AM; O'Mara AM; Li Y; Clauser SB; Bryant DM; Bearden JD; Gillis TA; Harness JK; Siegel RD; Paul DB; Cleeland CS; Schrag D; Sloan JA; Abernethy AP; Bruner DW; Minasian LM; Basch E;
    JAMA Oncol; 2015 Nov; 1(8):1051-9. PubMed ID: 26270597
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mode equivalence and acceptability of tablet computer-, interactive voice response system-, and paper-based administration of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
    Bennett AV; Dueck AC; Mitchell SA; Mendoza TR; Reeve BB; Atkinson TM; Castro KM; Denicoff A; Rogak LJ; Harness JK; Bearden JD; Bryant D; Siegel RD; Schrag D; Basch E;
    Health Qual Life Outcomes; 2016 Feb; 14():24. PubMed ID: 26892667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of different recall periods for the US National Cancer Institute's PRO-CTCAE.
    Mendoza TR; Dueck AC; Bennett AV; Mitchell SA; Reeve BB; Atkinson TM; Li Y; Castro KM; Denicoff A; Rogak LJ; Piekarz RL; Cleeland CS; Sloan JA; Schrag D; Basch E
    Clin Trials; 2017 Jun; 14(3):255-263. PubMed ID: 28545337
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging of acute and subacute toxicities of cancer therapy in children.
    Chavhan GB; Babyn PS; Nathan PC; Kaste SC
    Pediatr Radiol; 2016 Jan; 46(1):9-20; quiz 6-8. PubMed ID: 26459011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late effects in childhood cancer survivors and survivorship issues.
    Haupt R; Jankovic M; Hjorth L; Skinner R
    Epidemiol Prev; 2013; 37(1 Suppl 1):266-73. PubMed ID: 23585450
    [No Abstract]   [Full Text] [Related]  

  • 8. High risk of symptomatic cardiac events in childhood cancer survivors.
    van der Pal HJ; van Dalen EC; van Delden E; van Dijk IW; Kok WE; Geskus RB; Sieswerda E; Oldenburger F; Koning CC; van Leeuwen FE; Caron HN; Kremer LC
    J Clin Oncol; 2012 May; 30(13):1429-37. PubMed ID: 22473161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pattern of adverse drug reactions notified by spontaneous reporting in an Indian tertiary care teaching hospital.
    Jose J; Rao PG
    Pharmacol Res; 2006 Sep; 54(3):226-33. PubMed ID: 16781163
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trivalent Influenza Vaccine Adverse Event Analysis Based On MedDRA System Organ Classes Using VAERS Data.
    Tao C; Du J; Cai Y; Chen Y
    Stud Health Technol Inform; 2015; 216():1076. PubMed ID: 26262375
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late effects of treatment in children with cancer.
    Neglia JP
    Semin Pediatr Surg; 1993 Feb; 2(1):29-36. PubMed ID: 8062020
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Drug Reactions in Children: The Double-Edged Sword of Therapeutics.
    Elzagallaai AA; Greff M; Rieder MJ
    Clin Pharmacol Ther; 2017 Jun; 101(6):725-735. PubMed ID: 28295234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0.
    Chen AP; Setser A; Anadkat MJ; Cotliar J; Olsen EA; Garden BC; Lacouture ME
    J Am Acad Dermatol; 2012 Nov; 67(5):1025-39. PubMed ID: 22502948
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Adverse drug reactions in children].
    Jaffan L; Läer S
    Ther Umsch; 2011 Jan; 68(1):34-40. PubMed ID: 21184392
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adverse drug reactions in neonates: could we be documenting more?
    Hawcutt DB; O'Connor O; Turner MA
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):807-20. PubMed ID: 25225053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Childhood cancer surviving].
    Tabone MD; Sommelet D
    Arch Pediatr; 2006 Jun; 13(6):607-9. PubMed ID: 16690270
    [No Abstract]   [Full Text] [Related]  

  • 17. Treating paediatric malignancies.
    Stevens R
    Practitioner; 1992 Apr; 236(1513):395-8. PubMed ID: 1454702
    [No Abstract]   [Full Text] [Related]  

  • 18. The late effects of cancer therapy in childhood.
    Morris Jones PH
    Br J Cancer; 1991 Jul; 64(1):1-2. PubMed ID: 1854606
    [No Abstract]   [Full Text] [Related]  

  • 19. The first step to integrating the child's voice in adverse event reporting in oncology trials: a content validation study among pediatric oncology clinicians.
    Reeve BB; Withycombe JS; Baker JN; Hooke MC; Lyons JC; Mowbray C; Wang J; Freyer DR; Joffe S; Sung L; Tomlinson D; Gold SH; Hinds PS
    Pediatr Blood Cancer; 2013 Jul; 60(7):1231-6. PubMed ID: 23335328
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Severity of health conditions identified in a pediatric cancer survivor program.
    Wasilewski-Masker K; Mertens AC; Patterson B; Meacham LR
    Pediatr Blood Cancer; 2010 Jul; 54(7):976-82. PubMed ID: 20108334
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.